Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
…, P Bertazzoni, M Valentini, E Orlandi… - The American journal of …, 2004 - Elsevier
PURPOSE: To assess life expectancy and prognostic factors for survival in patients with
polycythemia vera and essential thrombocythemia. METHODS: The study sample consisted of …
polycythemia vera and essential thrombocythemia. METHODS: The study sample consisted of …
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic …
…, I Iacobucci, M Amabile, E Abruzzese, E Orlandi… - Clinical Cancer …, 2006 - AACR
Purpose: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL
inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients. …
inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients. …
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms
…, S Rattotti, R Riboni, A Corso, E Orlandi… - Blood, The Journal …, 2013 - ashpublications.org
A study has shown that MYD88 (L265P) is a recurring somatic mutation in Waldenström's
macroglobulinemia (WM). We developed an allele-specific polymerase chain reaction (PCR) …
macroglobulinemia (WM). We developed an allele-specific polymerase chain reaction (PCR) …
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
…, TC Greiner, WC Chan, EM Orlandi… - Blood, The Journal …, 2013 - ashpublications.org
Richter syndrome (RS) occurs in up to 15% of patients with chronic lymphocytic leukemia (CLL).
Although RS, usually represented by the histologic transformation to a diffuse large B-…
Although RS, usually represented by the histologic transformation to a diffuse large B-…
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations …
…, S Paolini, S Merante, E Orlandi… - Blood, The Journal …, 2009 - ashpublications.org
Dasatinib and nilotinib are tyrosine kinase inhibitors (TKIs) developed to overcome imatinib
resistance in Philadelphia-positive leukemias. To assess how Bcr-Abl kinase domain …
resistance in Philadelphia-positive leukemias. To assess how Bcr-Abl kinase domain …
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second …
…, P Bresciani, M Salvucci, D Russo, S Sica, E Orlandi… - Cancer, 2014 - Wiley Online Library
BACKGROUND Patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic
leukemia (ALL) frequently relapse on imatinib with acquisition of BCR‐ABL kinase domain (…
leukemia (ALL) frequently relapse on imatinib with acquisition of BCR‐ABL kinase domain (…
Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic …
…, D Vallisa, P Bernuzzi, E Orlandi… - … Journal of the …, 2004 - Wiley Online Library
BACKGROUND Splenic and nodal marginal zone lymphomas (MZL) are subtypes of
marginal zone‐derived neoplasms. Due to their rarity, little is known concerning their relation, …
marginal zone‐derived neoplasms. Due to their rarity, little is known concerning their relation, …
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus
…, MS Bissetti, G Numico, A Gava, E Orlandi… - Critical reviews in …, 2015 - Elsevier
Background Head and neck cancer (HNC) and its therapy are associated with acute and late
swallowing dysfunction. Consensus guidelines regarding evaluation and management are …
swallowing dysfunction. Consensus guidelines regarding evaluation and management are …
Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features.
M Lazzarino, E Orlandi, M Paulli, E Boveri… - Journal of clinical …, 1993 - ascopubs.org
PURPOSE To evaluate the clinical features of presentation, the morphologic and
immunohistochemical pattern, the modality of spread, and the response to current treatments of …
immunohistochemical pattern, the modality of spread, and the response to current treatments of …
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature …
…, L Vassalli, S Grisanti, S Salgarello, E Orlandi… - Critical reviews in …, 2016 - Elsevier
Radiotherapy alone or in combination with chemotherapy and/or surgery is the typical treatment
for head and neck cancer patients. Acute side effects (such as oral mucositis, dermatitis, …
for head and neck cancer patients. Acute side effects (such as oral mucositis, dermatitis, …
